# Completeness Review: AIAutomatepharmaceutical

- **Review date:** 2026-07-18
- **Assessment basis:** Static source and configuration inspection only. Dependencies were not installed, and no build, database migration, external integration, or runtime workflow was executed.

## Classification

**Prototype-demo**

## Verdict

The repository presents a broad life-sciences decision support surface (70 source files and 21 route modules), but the static evidence is characteristic of a generated prototype. Pages and endpoints demonstrate concepts; they do not establish a verified execution path for use curated compound, trial, medication, and patient data in a traceable evidence workflow.

## Why it is not complete

- 23 files are explicitly named as gap/gap-feature implementations; route/page count therefore overstates completed product capability.
- 21 files reference model-provider or chat-completion behavior; these generic LLM paths are not a substitute for deterministic domain execution, grounding, or evaluation.
- 27 files contain mock, sample, placeholder, or random-data signals, leaving important outcomes disconnected from authoritative systems.
- No recognizable application test files were found in the inspected tree.
- No CI workflow was found to continuously verify builds, tests, migrations, or security checks.
- No environment example/template was found, so required configuration and secret boundaries are undocumented.

## Needed features

- 1. Implement a workflow to use curated compound, trial, medication, and patient data in a traceable evidence workflow.
- 2. Connect validated biomedical sources, trial registries, terminology services, and governed clinical systems; replace seed/demo records with durable, synchronized data and explicit failure handling.
- 3. Evaluate retrieval, interaction/risk rules, uncertainty, and subgroup performance against expert-reviewed cases.
- 4. Enforce clinical-use boundaries, consent, provenance, privacy, and mandatory professional review.
- 5. Add contract, integration, authorization, migration, and end-to-end tests in CI, plus a documented non-destructive deployment/run path.

## Risks or launch blockers

- Credential/secret fallback or demo-password patterns occur in 3 files and must be removed or made development-only.
- The root launcher can terminate unrelated processes occupying configured ports.
- The root launcher seeds, creates, migrates, or otherwise mutates database state during startup.
- The root launcher installs dependencies at run time, reducing reproducibility and expanding supply-chain risk.
- Ungrounded or malformed model output can become a domain action unless schemas, evidence, evaluations, and approval gates are added.

## Evidence inspected

- `backend/package.json` — declared scripts, runtime dependencies, and application boundaries.
- `frontend/package.json` — declared scripts, runtime dependencies, and application boundaries.
- `backend/src/server.js` — service composition, middleware, and registered routes.
- `backend/src/routes/ai.js` — implemented API surface and domain/AI request handling.
- `backend/src/routes/aiFeatures.js` — implemented API surface and domain/AI request handling.
- `backend/src/routes/auth.js` — implemented API surface and domain/AI request handling.

## Recommended next action

Treat this as a prototype: select one narrow life-sciences decision support outcome, remove or quarantine generated gap routes, and implement that outcome end to end with real data, deterministic rules, and tests before adding features.

## Implementation progress

**Local status:** The locally actionable traceable-evidence foundation is implemented. It is not a clinical device and does not claim clinical, regulatory, subgroup, terminology, or professional validation.

- **Needed feature 1 — implemented locally:** `backend/src/routes/evidenceCases.js`, `backend/src/domain/evidenceWorkflow.js`, and `backend/migrations/003_pharma_evidence_cases.sql` store pseudonymous subjects, compounds, medications, versioned source hashes, interaction rules, consent basis, uncertainty, idempotency, review state, and immutable evidence history.
- **Needed feature 2 — bounded, externally blocked:** `/api/evidence-cases/external-capabilities` reports biomedical, trial-registry, terminology, clinical-system, and regulatory adapters unavailable. Real connections require governed credentials, data-use agreements, validated terminology versions, consent mapping, and controlled environments.
- **Needed feature 3 — local rules/evidence evaluation implemented; expert evaluation blocked:** deterministic summaries expose source/rule counts, high-severity rules, uncertainty, mandatory review, and prohibition of automated clinical action. Fixtures in `backend/tests/evidenceWorkflow.test.js` cover provenance, privacy, and approval. Retrieval quality and subgroup performance require expert-reviewed datasets.
- **Needed feature 4 — implemented locally:** direct patient identifiers and autonomous diagnosis/prescribing/dose-change requests are rejected; authenticated tenant-scoped cases require independent licensed-role approval and credential/jurisdiction attestation; event history is immutable.
- **Needed feature 5 — implemented locally:** a safe base migration plus evidence migration, explicit bootstrap/migrate/guarded-seed scripts, non-destructive start, tracked env/runtime validation, clinical boundary documentation, tests, and CI definitions for repeat migrations and frontend build are present.
- **Risk closure:** JWT/database fallbacks, startup migration/install/seed/port-kill behavior, displayed demo credentials, and mounted unvalidated AI/gap/regulatory/provider routes were removed. Database migrations no longer run implicitly on module import.
- **Validation performed:** 4/4 domain tests passed; JavaScript, shell, and Git whitespace checks passed. Dependencies were absent, so frontend build was not run. No clinical database, registry, terminology, regulatory provider, or database migration was executed locally.
